Please login to the form below

Not currently logged in
Email:
Password:

Bamboo Therapeutics

This page shows the latest Bamboo Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Catalent preps for complex therapy boom with $1.2bn Paragon buy

Catalent preps for complex therapy boom with $1.2bn Paragon buy

Last month, Pfizer paid around $640m for a 15% stake in Vivet Therapeutics, while Biogen snapped up Nightstar Therapeutics for $800m and Roche acquired Spark Therapeutics in February for $4.3bn. ... And in 2018, Novartis’ bought AveXis for $8.7bn to

Latest news

  • Pfizer abandons antibody for Duchenne Pfizer abandons antibody for Duchenne

    News of the setback spurred modest gains in the share price of Sarepta, which sells exon-skipping therapy Exondys 51 (eteplirsen) in the US and Europe, as well as PTC Therapeutics ... Pfizer still has an iron in the DMD fire, in the form of its Bamboo

  • Pfizer buys gene therapy specialist Bamboo Pfizer buys gene therapy specialist Bamboo

    Pfizer has made a play for a larger chunk of the emerging gene therapy market, agreeing a $700m deal to acquire Bamboo Therapeutics. ... Another $495m will go to Bamboo's investors if its gene therapy programmes make it through development and onto the

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    $14bn, antibiotic business interests from AstraZeneca for $1.4bn and Bamboo Therapeutics for $645m. ... 690. Bamboo Therapeutics (US). Pfizer (US). Company acquisition. Preclinical gene therapies and manufacturing plant.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics